Pharma BD Deal Intelligence
Merck's $9.5B buy of Cubist bought its way into the antibiotics-resistance space just as the superbug crisis was peaking commercially. The deal never became the growth engine Merck needed—an outcome score in the low 40s marks this one a bust, not the anchor of an infectious-disease franchise.
Merck acquired Cubist Pharmaceuticals for $9.5B, an antibiotic-focused pharmaceutical firm.
Combining Cubist's antibiotic expertise with Merck's global reach will strengthen the company's position in hospital acute care, with the deal expected to add…
Merck to acquire Cubist Pharmaceuticals for $102 per share in cash, representing a 35% premium to Cubist's average stock price, with total transaction value of…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck acquired Cubist Pharmaceuticals for $9.5B, an antibiotic-focused pharmaceutical firm.
2.8M US cases/yr · $45.0B Global Anti-Infectives Market (2015) · $1.1B Cubicin Revenue (2014)
Merck acquired Cubist Pharmaceuticals for $9.5B to become a leader in hospital antibiotics. Cubist's crown jewel was Cubicin (daptomycin), the leading IV antibiotic for Gram-positive infections including MRSA. With $1.1B in annual sales and a pipeline including ceftolozane/tazobactam (Zerbaxa) for Gram-negative infections, Cubist offered Merck a strong hospital anti-infectives franchise.
The hospital antibiotic market was dominated by generic beta-lactams, with Cubicin as the largest branded antibiotic. Pfizer (Zyvox franchise), Allergan (Avycaz/Dalvance), and Tetraphase competed for resistant infection market share. Merck's acquisition gave it both Cubicin and Zerbaxa, but Cubicin faced generic daptomycin entry in 2017. The broader antibiotics market has struggled commercially despite growing resistance concerns, with multiple companies exiting (Achaogen bankruptcy, Melinta restructuring).
US court invalidated key patents enabling generic entry by 2016 vs 2019. Part of Merck & Co. Inc.'s $9.5B deal to acquire Cubist Pharmaceuticals.
Merck & Co. Inc. completed its acquisition of Cubist Pharmaceuticals for $9.5B. Merck acquired Cubist Pharmaceuticals for $9.5B, an antibiotic-focused pharmaceutical firm.
Closed early research in Lexington, MA during integration. Part of Merck & Co. Inc.'s $9.5B deal to acquire Cubist Pharmaceuticals.
FDA approved Zerbaxa for hospital-acquired pneumonia. Part of Merck & Co. Inc.'s $9.5B deal to acquire Cubist Pharmaceuticals.
Same-day patent invalidation of Cubicin. R&D shut down. $9.5B excessive. Assessment of Merck & Co. Inc.'s $9.5B acquisition of Cubist Pharmaceuticals and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Cubist Pharmaceuticals, Inc. (this deal) | 2014 | $9.5B | 41 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2014 deals · Merck & Co. Inc. deals · Infectious Disease deals